Sunday , October 22 2017
Home / Resources / Videos / ADA 2017 / Exclusive: Dr Bruce Neal Discusses Canagliflozin’s Potential for Heart Failure Prevention

Exclusive: Dr Bruce Neal Discusses Canagliflozin’s Potential for Heart Failure Prevention

Neal1Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have an exclusive interview from ADA 2017.

The CANVAS study’s outcomes were “a positive first step” in proving that canagliflozin can be used for the primary prevention of heart failure in patients with diabetes, but more evidence is needed, according to the study’s lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California.

 

Featured videos include:

Pt.1: CANVAS Program and Cardiovascular Event Reduction

Pt.2: CANVAS Program and Renal Protection

Pt.3: CANVAS Program Compared to Other Studies

Pt.4: CANVAS Program, What Should be Taken Away

Pt.5: FDA SGLT2 Guidelines

Pt.6: Adverse Effects for SGLT2

or view the complete interview here: Complete Interview